Active substance
Valproic acid
- SFDA 22
- US FDA 67
- Health Canada 17
- US price lines 14
- NHS prices 23
- WHO EML 3
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DEPAKINE 200MG TABS | 200 mg | Gastro-resistant tablet · Oral use | 40 Blister | SAR 18.45 | NCE · Prescription | sanofi-aventis FRANCE | Valid |
| DEPAKINE 200MG-ML SOLU. | 200 mg/ml | Oral solution · Oral use | 1 Bottle | SAR 16.35 | NCE · Prescription | sanofi-aventis FRANCE | Valid |
| DEPAKINE 400MG-4ML Powder for injection | 100 mg/ml | Powder and solvent for solution for injection · Intravenous use | 4 Vial | SAR 128.35 | NCE · Prescription | Sanofi Aventis France | Valid |
| DEPAKINE 500MG TABS | 500 mg | Gastro-resistant tablet · Oral use | 40 Blister | SAR 32.20 | NCE · Prescription | sanofi-aventis FRANCE | Valid |
| DEPAKINE 57.64MG-ML SYRUP | 57.64 mg/ml | Syrup · Oral use | 1 Bottle | SAR 20.85 | NCE · Prescription | sanofi-aventis | Valid |
| DEPAKINE CHRONO 500MG TABS | 500 mg | Prolonged-release film-coated tablet · Oral use | 30 Bottle | SAR 51.85 | Generic · Prescription | Sanofi Aventis France | Valid |
| Sodium Valproate | 100 mg/ml | Solution for injection/infusion · Intravenous use | 5 Vial | SAR 160.45 | Generic · Prescription | Seacross Pharmaceuticals Ltd | Valid |
| VALOPRA 200 MG-ML SOLUTION | 200 mg/ml | Solution · Oral use | 1 Bottle | SAR 11.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VALOPRA 57.64 MG-ML SYRUP | 57.64 mg/ml | Syrup · Oral use | 1 Bottle | SAR 11.25 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VALPOHARDT 100 mg/ml solution for injection or infusion | 100 mg/ml | Solution for injection/infusion · Intravenous use | 5 Ampoule | SAR 246.10 | Generic · Prescription | WOCKHARDT UK LIMITED | Valid |
| Votellaz | 500 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 46.65 | Generic · Prescription | Aurobindo Pharma Limited | Valid |
| DEPAKINE 200MG TABS | 200 mg | Gastro-resistant tablet · Oral use | 40 Blister | SAR 21.70 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| DEPAKINE 200MG-ML SOLU. | 200 mg/ml | Oral solution · Oral use | 1 Bottle | SAR 16.35 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| DEPAKINE 400MG-4ML Powder for injection | 100 mg/ml | Powder and solvent for solution for injection · Intravenous use | 4 Vial | SAR 195.00 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| DEPAKINE 500MG TABS | 500 mg | Gastro-resistant tablet · Oral use | 40 Blister | SAR 37.90 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| DEPAKINE 57.64MG-ML SYRUP | 40 mg/ml | Syrup · Oral use | 1 Bottle | SAR 20.85 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| DEPAKINE CHRONO 500MG TABS | 500 mg | Prolonged-release film-coated tablet · Oral use | 30 Blister | SAR 61.00 | Generic · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| EPIVAL 200MG\5ML SYRUP | 40 mg/ml | Syrup · Oral use | 1 Bottle | SAR 7.50 | Generic · Prescription | UNITED PHARMACEUTICAL CO. | Withdrawn by MAH · Not Marketed |
| VALIREC 200 MG-5 ML SYRUP | 40 mg | Syrup · Oral use | 1 Bottle | SAR 13.10 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| VALOPIN 200 MG E-C TABLETS | 200 mg | Gastro-resistant tablet · Oral use | 40 Blister | SAR 15.20 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| VALOPIN 200MG\5ML SYRUP | 40 mg/ml | Syrup · Oral use | 1 Bottle | SAR 8.35 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| VALOPIN 500 MG E-C TABLETS | 500 mg | Gastro-resistant tablet · Oral use | 30 Blister | SAR 21.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BIPOLAR I DEPRESSION; ACUTE MANIA; ANXIETY DISORDERS; BIPOLAR I DISORDER MAINTENANCE; BIPOLAR II DISORDER; DIABETIC NEUROPATHY; DRAVET SYNDROME; JUVENILE MYOCLONIC SEIZURES; LENNOX GASTAUT SYNDROME AND TONIC OR ATONIC SEIZURES; MIGRAINE/ HEADACHE; MYOCLONIC SEIZURES
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DEPAKOTE | EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID; EQ 125MG VALPROIC ACID | tablet, delayed release · oral | ABBVIE | Prescription | 10 Mar 1983 |
| DEPAKOTE | EQ 125MG VALPROIC ACID | capsule, delayed rel pellets · oral | ABBVIE | Prescription | 12 Sep 1989 |
| VALPROIC ACID | 250MG | capsule · oral | CATALENT | Prescription | 29 Oct 1991 |
| VALPROIC ACID | 250MG/5ML | syrup · oral | ANI PHARMS | Prescription | 25 Aug 1992 |
| VALPROIC ACID | 250MG | capsule · oral | BIONPHARMA | Prescription | 29 Jun 1993 |
| DEPAKOTE ER | EQ 500MG VALPROIC ACID; EQ 250MG VALPROIC ACID | tablet, extended release · oral | ABBVIE | Prescription | 4 Aug 2000 |
| VALPROIC ACID | 250MG/5ML | syrup · oral | PHARM ASSOC | Prescription | 15 Dec 2000 |
| VALPROIC ACID | 250MG/5ML | syrup · oral | CHARTWELL RX | Prescription | 22 Dec 2000 |
| VALPROATE SODIUM | EQ 100MG BASE/ML | injectable · injection | SAGENT | Prescription | 14 Nov 2002 |
| DEPAKOTE ER | 250MG; 500MG | tablet, extended release · oral | ABBOTT | Prescription | 20 Dec 2002 |
| VALPROATE SODIUM | EQ 100MG BASE/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 26 Jun 2003 |
| DEPAKOTE ER | 250MG; 500MG | tablet, extended release · oral | ABBVIE INC | Prescription | 24 Mar 2008 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID; EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, delayed release · oral | UPSHER SMITH LABS | Prescription | 29 Jul 2008 |
| DIVALPROEX SODIUM | EQ 500MG VALPROIC ACID; EQ 250MG VALPROIC ACID; EQ 125MG VALPROIC ACID | tablet, delayed release · oral | INVATECH | Prescription | 29 Jul 2008 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID; EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, delayed release · oral | SUN PHARM INDS | Prescription | 29 Jul 2008 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID; EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, delayed release · oral | DR REDDYS LABS LTD | Prescription | 29 Jul 2008 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID; EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, delayed release · oral | CHARTWELL RX | Prescription | 31 Jul 2008 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID; EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, delayed release · oral | ORBION PHARMS | Prescription | 25 Nov 2008 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID | capsule, delayed rel pellets · oral | DR REDDYS LABS LTD | Prescription | 23 Jan 2009 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID | capsule, delayed rel pellets · oral | ZYDUS PHARMS USA INC | Prescription | 27 Jan 2009 |
| DIVALPROEX SODIUM | EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, extended release · oral | MYLAN | Prescription | 29 Jan 2009 |
| DIVALPROEX SODIUM | EQ 500MG VALPROIC ACID; EQ 250MG VALPROIC ACID | tablet, extended release · oral | SCIEGEN PHARMS | Prescription | 10 Feb 2009 |
| DIVALPROEX SODIUM | EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, extended release · oral | ZYDUS PHARMS USA INC | Prescription | 27 Feb 2009 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID; EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, delayed release · oral | ZYDUS PHARMS USA INC | Prescription | 5 Mar 2009 |
| DIVALPROEX SODIUM | EQ 125MG VALPROIC ACID; EQ 250MG VALPROIC ACID; EQ 500MG VALPROIC ACID | tablet, delayed release · oral | PRINSTON INC | Prescription | 30 Nov 2009 |
42 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-DIVALPROEX | 02239698 | 125 MG | TABLET (DELAYED-RELEASE) · ORAL | APOTEX INC |
| APO-DIVALPROEX | 02239699 | 250 MG | TABLET (DELAYED-RELEASE) · ORAL | APOTEX INC |
| APO-DIVALPROEX | 02239700 | 500 MG | TABLET (DELAYED-RELEASE) · ORAL | APOTEX INC |
| APO-VALPROIC ACID | 02238048 | 250 MG | CAPSULE · ORAL | APOTEX INC |
| DEPAKENE | 00443832 | 250 MG / 5 ML | SOLUTION · ORAL | BGP PHARMA ULC |
| EPIVAL | 00596418 | 125 MG | TABLET (DELAYED-RELEASE) · ORAL | BGP PHARMA ULC |
| EPIVAL | 00596426 | 250 MG | TABLET (DELAYED-RELEASE) · ORAL | BGP PHARMA ULC |
| EPIVAL | 00596434 | 500 MG | TABLET (DELAYED-RELEASE) · ORAL | BGP PHARMA ULC |
| JAMP DIVALPROEX | 02551152 | 250 MG | TABLET (DELAYED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| JAMP DIVALPROEX | 02551160 | 500 MG | TABLET (DELAYED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| JAMP VALPROIC ACID ORAL SOLUTION | 02532441 | 250 MG / 5 ML | SOLUTION · ORAL | JAMP PHARMA CORPORATION |
| MYLAN-DIVALPROEX | 02458926 | 125 MG | TABLET (DELAYED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-DIVALPROEX | 02458934 | 250 MG | TABLET (DELAYED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-DIVALPROEX | 02459019 | 500 MG | TABLET (DELAYED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| ODAN-VALPROIC ACID | 02549190 | 250 MG / 5 ML | SOLUTION · ORAL | ODAN LABORATORIESLTD |
| PMS-VALPROIC ACID | 02230768 | 250 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
| PMS-VALPROIC ACID | 02236807 | 250 MG / 5 ML | SOLUTION · ORAL | PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DEPAKOTE DR 125 MG SPRINKLE CP | $1.96951 | per EA | 23 Sep 2026 |
| US NADAC | DEPAKOTE DR 125 MG TABLET | $2.05517 | per EA | 23 Sep 2026 |
| US NADAC | DEPAKOTE DR 250 MG TABLET | $4.0456 | per EA | 23 Sep 2026 |
| US NADAC | DEPAKOTE DR 500 MG TABLET | $7.45557 | per EA | 23 Sep 2026 |
| US NADAC | DEPAKOTE ER 250 MG TABLET | $3.68703 | per EA | 23 Sep 2026 |
| US NADAC | DEPAKOTE ER 500 MG TABLET | $6.49213 | per EA | 23 Sep 2026 |
| US NADAC | DIVALPROEX DR 125 MG CAP SPRNK | $0.20079 | per EA | 23 Sep 2026 |
| US NADAC | DIVALPROEX SOD DR 125 MG TAB | $0.05494 | per EA | 23 Sep 2026 |
| US NADAC | DIVALPROEX SOD DR 250 MG TAB | $0.08564 | per EA | 23 Sep 2026 |
| US NADAC | DIVALPROEX SOD DR 500 MG TAB | $0.16081 | per EA | 23 Sep 2026 |
| US NADAC | DIVALPROEX SOD ER 250 MG TAB | $0.12984 | per EA | 23 Sep 2026 |
| US NADAC | DIVALPROEX SOD ER 500 MG TAB | $0.19434 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Sodium valproate 100mg modified-release granules sachets sugar free | £30.00 | 30 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 100mg tablets | £1.68 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 150mg modified-release capsules | £2.76 | 30 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 1g modified-release granules sachets sugar free | £12.30 | 30 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 200mg gastro-resistant tablets | £1.99 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 200mg modified-release tablets | £3.50 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 200mg/5ml oral solution | £9.33 | 300 ml | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 200mg/5ml oral solution sugar free | £12.55 | 300 ml | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 250mg modified-release granules sachets sugar free | £30.00 | 30 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 300mg modified-release capsules | £4.56 | 30 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 300mg modified-release tablets | £5.24 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium valproate 300mg/3ml solution for injection ampoules | £35.00 | 5 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 5.1.1. Antiseizure medicines · core
Epilepsy or seizures
Oral > Liquid: 200 mg per 5 mL | Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable) - 5.1.1. Antiseizure medicines · complementary
Status epilepticus
Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule - 24.2.2. Medicines for bipolar disorders · core
Bipolar or related disorders
Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)
Safety signals and safety-related labeling changes
- US FDA 31 Mar 2026 DEPAKOTE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2026 DEPAKOTE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2026 DEPAKOTE ER — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2026 STAVZOR — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 May 2020 DEPAKENE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 19 May 2020 DEPAKENE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.